What question did this study set out to answer?

This research aims to evaluate the efficacy and safety of fostamatinib in patients with warm autoimmune hemolytic anemia and Evans syndrome.

March 21, 2026Open Access

View Full Paper

A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome

JLJ. LópezUniversity of Washington LSLipei Shao DJDebbie JiangHarvard University

Key Points

This research aims to evaluate the efficacy and safety of fostamatinib in patients with warm autoimmune hemolytic anemia and Evans syndrome.
Conducted a multicentre retrospective analysis
Evaluated treatment responses and side effects
Assessed molecular response correlates in a patient subset
Achieved a 46% durable response rate
Observed a 73% reduction in steroid use
Reported side effects in 23% of patients, including hypertension and neutropenia
Identified correlations between migration inhibitory factor, naïve T-cells, and treatment response in a subset of eight patients.

Abstract

Fostamatinib had 46% durable response, with 73% steroid reduction, in this multicentre retrospective study of refractory wAIHA/ES. Hypertension, gastrointestinal (GI) distress and neutropenia occurred in 23%. Only one patient required drug discontinuation and one patient dose reduction. In an eight-patient subset, migration inhibitory factor (MIF) levels, naïve (CD62Lhi) T-cell and HLA-DRhi monocyte subsets each correlated with treatment response.

AIに質問

Bookmark

View Full Paper

AIに質問

Bookmark

View Full Paper

A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome

Key Points

Abstract

Cite This Study